EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive
Recent news

The world’s largest haematology conference will be held in person and virtually this year from the 11th to 14th of December. Despite the continued difficulties and limitations posed by the coronavirus pandemic, this year’s American Society of Haematology Annual Meeting will feature, more than 200 abstracts in myeloma and AL amyloidosis.

Newly emerging treatments for myeloma such as CAR-T, bispecific T-cell engagers, and new data on existing combinations will be some of the topics presented during the conference. MPE anticipates the myeloma and AL amyloidosis highlights will include the following sessions:

 

General sessions:
  • Challenges in Multiple Myeloma Treatment – Maria-Victoria Mateos. Click here to read the abstract.
  • Challenges in Multiple Myeloma Treatment – Live Q&A – Maria-Victoria Mateos, Noopur S. Raje, MD., Ashley E. Rosko, MD. Click here to read the abstract.
  • Minimal Residual Disease in Multiple Myeloma – Why, When, Where, and How-Noopur S. Raje, MD. Click here to read the abstract.
  • A Glimpse into the Future of Myeloma Patient Management- Hearn Jay Cho, MD., PhD., Amrita Y. Krishnan, MD, Elisabet E. Manasanch, MD., Paul G. Richardson, MD., Nina Shah, MD., A. Keith Stewart, MBChB. Click here to read the abstract
  • Multiple Myeloma Real- World Data for Research (HARMONY)- Mario Boccadoro. Click here to read the abstract.

 

Newly diagnosed myeloma:
  • Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin – Jacob P. Laubach.  Click here to read the abstract.
  • Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 – Herve Avet Loiseau, MD, PhD. Click here to read the abstract.
  • Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant- Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial – Hartmut GoldSchmidt, MD. Click here to read the abstract.
  • Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial– Martin F. Kaiser, MD, FRCP, FRCPath. Click here to read the abstract.
  • Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial – Laura Rosinol. Click here to read the abstract.
  • First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios- Rafael Fonseca. Click here to read the abstract.
  • Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study– Kaz Groen, MD. Click here to read the abstract.
  • Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly- Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial – Harmut GoldSchmidt, MD. Click here to read the abstract.
  • Redefining Frontline Therapy in Transplant Ineligible Multiple Myeloma Patients: Maia 5-Year Update Including Overall Survival – Thomas S. Lin, Md, PhD. Click here to read the abstract.

 

Relapse/ refractory myeloma:
  • Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.– Shaji K. Kumar, MD. Click here to read the abstract.
  • Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial – Sagar Lonial, MD, FACP. Click here to read the abstract.
  • DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma- Natalie S. Callander, MD. Click here to read about the abstract.
  • Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study- Dan. T. Vogl. Click here to read the abstract.
  • Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma – Jonathan L. Kaufman, MD. Click here to read the abstract.

 

Frail patients:
  • Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials- Gordon Cook, MD. Click here to read the abstract.
  • Treatment of Older Adult to Frail Patients with Multiple Myeloma- Ashley E. Rosko, MD. Click here to read the abstract.

 

Novel therapies:

Bi specifics:

  • Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study – Suzanne Trudel, MD. Click here to read the abstract.
  • Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma – Ajai Chari, MD. Click here to read the abstract.
  • Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma – Amrita Y. Krishna, MD. Click here to read the abstract.
  • Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) – Jeffrey A. Zonder, MD. Click here to read the abstract.
  • Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1 – Michael Sebag, MD, PhD. Click here to read the abstract.
  • Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma -Philippe Moreau, MD. Click here to read the abstract.
  • A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma- Shaji K. Kumar, MD. Click here to read the abstract.
  • ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma – Sammichell Stefano, PhD. Click here to read the abstract.
  • Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies(BiAbs)- Tarek H. Mouhieddine, MD. Click here to read the abstract.

CAR-T cells:

  • Advances in CAR-T Cell Therapy Across Hematologic Malignancies: from Pipeline to Clinical Practice – Jesús G. Berdeja, Michael R. Bishop, MD, Jae H Park, MD. Click here to read the abstract.
  • A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma – Ranjan Maity, PhD. Click here to read the abstract.
  • A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma. – Chunrui Li, MD, PhD. Click here to read the abstract.
  • Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma– Noopur S. Raje, MD. Click here to read the abstract.
  • Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple Myeloma– Thomas Martin. Click here to read the abstract.
  • Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study – Maria-Victoria Mateos. Click here to read the abstract.
  • Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma- Andrew J. Cowan, MD. Click here to read the abstract.
  • Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) – Aina Oliver- Caldés, MD. Click here to read the abstract.
  • Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma – Sham Mailankody, MBBS. Click here to read the abstract.
  • Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma- Sham Mailankody, MBBS. Click here to read the abstract.

Novel therapies and prognosis:

  • Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States – Bharat Nandakumar. Click here to read the abstract.

 

Patient diversity in clinical trials:
  • Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected by These Diseases? – Mycal casey, DO. Click here to read the abstract.
  • 4118 – Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years. (PAPER) Click here to read the abstract.

 

Diversity and equitable care:
  • 4116 – Racial Disparities in the Diagnostic Evaluation of Multiple Myeloma. (PAPER) Click here to read the abstract.
  • Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma – Nancy Gillis, MD. Click here to read the abstract.
  • Clinical and Biological Factors That Affect Presentation and Outcomes in Multiple Myeloma Patients with Excess Body Weight – Beatrice Razzo, MD. Click here to read the abstract.
  • Roots of Socioeconomic and Biological Disparities Among Hispanics with Multiple Myeloma- Rigoberto De Jesus Pizarro, MD. Click here to read the abstract.
  • Identifying Disparities in Survival Among Older Adults with Multiple Myeloma Based on Rural Versus Urban Residence – Sarah Addison, BS. Click here to read the abstract.
  • Overcoming Barriers to Equitable Care for Patients with Multiple Myeloma– Sikander Ailawadhi, MD, Craig E. Cole, MD, Stinchon R Michael Jr., RPh. Click here to read the abstract.
  • How Can We Ensure That Everyone Who Needs A Transplant Can Get One? – Live Q&A–Andrew S. Artz, MD MS, Navneet S. Majhail, MD, Vanderson Rocha, MD, PhD. Click here to read the abstract.

 

Patient voices and perspectives:
  • Is PFS the Right Endpoint to Assess Outcome of Maintenance Studies in Multiple Myeloma? Results of a Patient Survey Highlight Quality-of-Life As an Equally Important Outcome Measure – Anna Fleischer, MD. Click here to read the abstract.
  • A is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey – Noa Biran, MD, Suzanne Lentzsch, MD, PhD Ajay K. Nooka. Click here to read the abstract.
  • Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans – Rajshekhar Chakraborty, MD. Click here to read the abstract.

 

COVID-19 and myeloma:
  • Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment. – Oliver Van Oekelen, MD MSc. Click here to read the abstract.
  • Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study – Nathanael R Fillmore, PhD. Click here to read the abstract.

 

Smouldering myeloma:
  • Smouldering Multiple Myeloma- Evolving Diagnostic Criteria and Treatment Strategies- Rahma M Warsame, MD. Click here to read the abstract.
  • Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes – Shankara Anand, MS. Click here to read the abstract.

 

AL amyloidosis:
  • Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study – Raymond Comenzo, MD. Click here to read the abstract.
  • Safety and Tolerability of Cael-101 in Combination with Anti-Plasma Cell Dyscrasia Therapy in Patients with AL Amyloidosis: 1- Year Results from an Open-Label Phase 2 Trial- Jason Valent. Click here to read the abstract.
  • Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design- Morie A Gertz, MD, MACP. Click here to read the abstract.
  • Belantamab Mafadotin in Patients with Relapsed/Refractory AL Amyloidosis with Myeloma – Yifei Zhang, MD. Click here to read the abstract.
  • Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy – Blessie Elizabeth Nelson, MBBS. Click here to read the abstract.
  • Treatment Landscape for AL Amyloidosis: Daratumumab plus hyaluronidase- Rachel Ershler, MD. Click here to read the abstract.
  • Treatment Landscape for AL Amyloidosis- Clinical Discussant – Vaishali Sanchorawala, MD. Click here to read the abstract.






Recent news

» Myeloma diagnosis can take over 5 months and require more than 4 medical consultations with more than 3 different specialists

» The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myeloma

Leave a Reply

Your email address will not be published.

I accept the Privacy Policy